# Advisor Review - Gemini-3-Flash

**Role:** Academic advisor checking for fatal errors
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-02-27T21:02:36.633701
**Route:** Direct Google API + PDF
**Paper Hash:** 7813d5bd8dd40731
**Tokens:** 18838 in / 742 out
**Response SHA256:** 7a967714df2c78a1

---

I have reviewed the paper for fatal errors that would preclude submission to a journal. Below is my assessment.

### **1. DATA-DESIGN ALIGNMENT**
The paper’s empirical design is internally consistent with the data coverage.
*   **Treatment timing vs data coverage:** The study periods (Table 3, page 15) end in December 2024 (2024Q4). The Land Registry and EPC data (Section 3.1) both cover January 2015 through December 2024. This alignment is correct.
*   **Post-treatment observations:** The "Post-MEES" period begins April 2018. The data continues for over 6 years post-treatment, ensuring sufficient observations for the RDD.
*   **RDD cutoff:** The thresholds used (39, 55, 69, 81, 92) match the institutional EPC band definitions provided in Section 2.1. Figure 1 (page 8) confirms data exists on both sides of every cutoff.

### **2. REGRESSION SANITY**
All regression tables (Table 2, Table 3, Table 4, Table 9) were scanned for broken outputs.
*   **Standard Errors:** SEs are within normal ranges for log-price outcomes (ranging from 0.01 to 0.11). There are no instances where SE > 1000 or SE > 100 × |coefficient|.
*   **Coefficients:** All coefficients for the log outcomes are between -0.10 and +0.35, which is plausible for percentage effects (e.g., a 0.06 coefficient representing a ~6% price change).
*   **Impossible Values:** No negative $R^2$ (though $R^2$ is typically not reported for `rdrobust` outputs), no negative standard errors, and no "NA/NaN" entries in the result cells.

### **3. COMPLETENESS**
The paper is complete and ready for review.
*   **Placeholders:** Scanned for "TBD", "PLACEHOLDER", "XXX", and "Sun-Abraham". None found.
*   **Required Elements:** Regression tables (Tables 2, 3, 6, 7, 8, 9) consistently report effective sample sizes ($N$), standard errors in parentheses, and significance levels.
*   **Analyses:** All major claims (MEES decomposition, crisis amplification, and the owner-occupied placebo) are supported by corresponding tables and figures in the results and appendix sections.

### **4. INTERNAL CONSISTENCY**
*   **Numbers Match:** The 6.5% estimate for E/F cited in the abstract matches the 0.0648 coefficient in Table 2 (page 11). The 15.3% crisis estimate cited in the abstract matches the 0.1527 coefficient in Table 3 (page 15).
*   **Sample Consistency:** The total $N=85,795$ cited in the text matches the sum of observations by band in Table 1 (page 7).
*   **Timing Consistency:** The definitions for the four periods (Pre-MEES, Post-MEES, Crisis, Post-Crisis) on page 7 are applied consistently in Tables 3, 4, and 9.

**ADVISOR VERDICT: PASS**